Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Ultragenyx Pharmaceutical Inc (RARE) Going to Burn These Hedge Funds?

Page 1 of 2

Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players within the hedge fund industry can easily identify the undervalued and high-potential stocks that reside the ignored corners of equity markets. There are numerous small-cap stocks that have turned out to be great winners, which is one of the main reasons the Insider Monkey team pays close attention to the hedge fund activity in relation to these stocks.

Is Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) a splendid investment right now? The smart money is betting on the stock. The number of long hedge fund bets advanced by 1 lately. RARE was in 25 hedge funds’ portfolios at the end of September. There were 24 hedge funds in our database with RARE holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Validus Holdings, Ltd. (NYSE:VR), Guidewire Software Inc (NYSE:GWRE), and Colfax Corp (NYSE:CFX) to gather more data points.

Follow Ultragenyx Pharmaceutical Inc.
Trade (RARE) Now!

In the eyes of most market participants, hedge funds are perceived as worthless, outdated financial vehicles of the past. While there are over 8000 funds trading at present, Our researchers choose to focus on the bigwigs of this club, around 700 funds. Most estimates calculate that this group of people orchestrate most of the hedge fund industry’s total capital, and by tracking their unrivaled picks, Insider Monkey has revealed several investment strategies that have historically defeated the broader indices. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Now, we’re going to go over the key action surrounding Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

How have hedgies been trading Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)?

At the end of the third quarter, a total of 25 of the hedge funds tracked by Insider Monkey held long positions in this stock, a small change of 4% from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few notable hedge fund managers who were increasing their stakes significantly (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Visium Asset Management, managed by Jacob Gottlieb, holds the most valuable position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Visium Asset Management has an $60.8 million position in the stock, comprising 0.8% of its 13F portfolio. Sitting at the No. 2 spot is Millennium Management, managed by Israel Englander, which holds an $52.2 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other professional money managers that are bullish consist of Phill Gross and Robert Atchinson’s Adage Capital Management, Brian Ashford-Russell and Tim Woolley’s Polar Capital and Matthew A. Weatherbie’s Weatherbie Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!